FDA’s 2005 New Molecular Entity Total: 18, Including Five In December
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.